Journal article
Glycaemic control in patients with type 2 diabetes initiating second-line therapy: Results from the global DISCOVER study programme.
Kamlesh Khunti, Hungta Chen, Javier Cid-Ruzafa, Peter Fenici, Marilia B Gomes, Niklas Hammar, Linong Ji, Mikhail Kosiborod, Stuart Pocock, Marina V Shestakova, Iichiro Shimomura, Fengming Tang, Hirotaka Watada, Antonio Nicolucci, undefined DISCOVER investigators
Diabetes, Obesity and Metabolism: a journal of pharmacology and therapeutics | Published : 2020
DOI: 10.1111/dom.13866
Abstract
AIM: To assess glycaemic control and factors associated with poor glycaemic control at initiation of second-line therapy in the DISCOVER programme. MATERIALS AND METHODS: DISCOVER (NCT02322762 and NCT02226822) comprises two similar prospective observational studies of 15 992 people with type 2 diabetes (T2D) initiating second-line glucose-lowering therapy in 38 countries across six regions (Africa, Americas, South-East Asia, Eastern Mediterranean, Europe and Western Pacific). Data were collected using a standardized case report form. Glycated haemoglobin (HbA1c) levels were measured according to standard clinical practice in each country, and factors associated with poor glycaemic control (H..
View full abstract